CD65, CD11b (dim), CD4 (dim), and cytoplasmic myeloperoxidase, consistent with acute myelomonocytic leukemia. Chemotherapy was initiated, and the patient has been in durable remission for 24 months. This study was approved by the St Jude Children's Research Hospital Institutional Review Board.
Cytogenetic analysis performed on the patient's leukemic blasts revealed a t(10;11)(q22;q23) as the sole chromosomal abnormality in all 20 metaphases analyzed ( Figure 1a ). Metaphase FISH analysis using a probe that spans the entire MLL locus 6 (Oncor, Gaithersburg, MD, USA) demonstrated three signals, one of which was on the derivative chromosome 10, Rearrangement of MLL by the t(10;11)(q22;q23) translocation. (a) Cytogenetic analysis performed on bone marrow identified a t(10;11)(q22;q23) as the sole chromosomal abnormality in all metaphases examined. (b) Metaphase FISH performed on leukemic bone marrow cells using a probe that spans the MLL locus. (c) Southern blot analysis of HindIII-digested leukemic cell and normal PB leukocyte genomic DNA; the blot was hybridized with an MLL probe that spans the MBR. The germline and rearranged bands are 14.5 and 6.8 kb, respectively. The rearranged band in the patient sample is indicated by an arrowhead. Table 1 Genomic localization of TET gene family Gene NCBI accession
Celera accession
Chromosome Syntenic murine chromosomal region confirming that the observed t(10;11) involved the MLL gene ( Figure 1b) . Southern blots probed with an MLL cDNA probe that spans the major breakpoint region (MBR) revealed a 6.8 kb rearranged band in the leukemic DNA digested with HindIII ( Figure 1c) .
We utilized LDI-PCR to clone the translocation breakpoint. Genomic DNA from leukemic cells was digested with HindIII, ligated at low concentration, and subjected to two rounds of PCR using nested primers within exon 5 (Figure 2a) , which was 100% identical to intronic sequence within the KIAA1676 gene on chromosome 10q22. Based on its involvement in a t(10;11)-associated leukemia, we have designated this gene Ten-Eleven Translocation-1 (TET1). Just prior to submission of this manuscript, TET1 was independently identified as the partner gene in another case of AML containing t(10;11)(q22;q23). 5 In our case, the breakpoint within MLL intron 6 was 20 bp upstream of that reported by Ono et al, 5 whereas the breakpoint within TET1 intron 8 was 950 bp downstream of that reported by these investigators.
To independently confirm that TET1 was the translocation partner, RT-PCR analysis was performed on total RNA extracted from either leukemic cells or control peripheral blood leukocytes (PBL) using 5 0 and 3 0 primers derived from MLL exon 5 (MLL 5 0 -GCCTCAGCCACCTACTACAGGAC-3 0 ) and TET1 exon 9 (TET1 5 0 -GGAGCTGCTCATC-TTGAGGAATAAC-3 0 ), respectively ( Figure 2b ). RT-PCR performed on the leukemic sample, but not the control, generated a band of the predicted size. Expression of the reciprocal TET1-MLL transcript was not detected in RT-PCR analyses using two separate primer pairs (data not shown). Sequencing of the cloned RT-PCR product revealed, as predicted, a chimeric transcript consisting of MLL exon 6 fused in-frame to TET1 exon 9 ( Figure 2c ). TET1 is predicted to encode a protein of 2136 amino acids with a molecular mass of 235.3 kDa. TET1 contains a CXXC domain at position 583-624, a coiled-coil region near the C-terminus (position 2062-2091), and three candidate bipartite nuclear localization signals. 5 The MLL-TET1 fusion protein is predicted to have a molecular mass of 204.4 kDa and to retain the AT hooks, subnuclear localization domains, and the CXXC motif of MLL, as well as the coiled-coil region and AAA CAA AAA CCA AAA GAA AAG GAA AAA AAC CTT GAA GAT AAC TET1 is the member of a novel family of proteins. Amino-acid sequences of the human TET family members were aligned using a ClustalW algorithm. 8 Residues identical in all TET proteins are underlined and bold. Two regions (corresponding to residues 1431-1737 and 1991-2061 of TET1) are highly conserved among all three proteins.
Correspondence the most C-terminal nuclear localization domain of TET1 (Figure 2d ).
BLAST analysis of the NCBI and Celera databases identified two human proteins with significant homology to TET1, which we have designated as TET2 and TET3 (Celera accession numbers hCP38872 and hCP50515). They are 827 and 1143 amino-acid residues long, respectively, and may represent incomplete protein products. Multiple alignment analysis revealed two regions that were highly conserved among all human TET family members (Figure 3) . The first consists of a 307 amino-acid residue segment that shows 63% identity and 80% similarity between all three proteins. The second region located near the carboxy terminus consists of a 70 amino-acid residue segment (corresponding to residues 1991-2061 of TET1) and is 74% identical between all TET family members. Analysis of mouse and fruitfly databases identified three murine proteins (Celera accession numbers mCP1086 and mCP1483) and the Drosophila CG2083 gene product (NCBI accession number AAF47691) as sharing significant sequence homology with TET1. Genomic information for the human and murine TET genes is summarized in Table 1 .
To analyze the expression pattern of the TET genes, we performed PCR on a cDNA panel prepared from 24 adult and fetal human tissues (OriGene Technologies, Rockville, MD, USA) using primers specific for each of the TET genes (TET1 5 0 -CCTCCTTCCTCACCTCTCCTCAAGAC-3 0 , 5 0 -AGCCTTCAGAC CCAATGGTTATAG-3 0 ; TET2 5 0 -GCACACGCTGGAGGAGAAG CTACT-3 0 , 5 0 -CGAGGTGTCTTGCTCCGAGCATAC-3 0 ; or TET3 5 0 -GGAGCTTACCGAGACGCTGAGGAA-3 0 , 5 0 -AGACGGCAC TCTGGTGCTCTGTGT-3 0 ). As shown in Figure 4 , TET2 was widely expressed, whereas the other TET genes had more limited expression. TET2 was most frequently coexpressed with either TET1 or TET3. Expression of all three TET genes was observed only in muscle, adrenal gland, and fetal brain. Several organs expressed only TET2; however, expression of TET1 alone was seen only in salivary gland and fetal liver; expression of TET3 alone was not detected in any of the 24 tissues surveyed. Expression of TET1 within the hematolymphoid system was limited to spleen, with no detectable expression in bone marrow or PBL. TET1 was expressed in fetal liver, but not in its adult counterpart. Within the hematolymphoid system, TET3 expression was detected only in PBL. Taken together, these findings indicate that the expression of the TET family members is differentially regulated.
Six cases of AML have been described that harbor the t(10;11)(q22;q23), including the current case, and all, but one, have had a myelomonocytic or monoblastic immunophenotype. [2] [3] [4] [5] Of the five patients with available clinical information, one patient was pediatric and the remainder were adults, with mean and median ages of 29.8 and 35 years, respectively. Four of these patients relapsed and subsequently died, two because of persistent leukemia and two because of infectious complications. Although definitive conclusions regarding prognosis cannot be made given the small number of patients, it appears that the presence of the t(10;11)(q22;q23), like several other MLL translocations, confers a poor prognosis.
In summary, we have demonstrated that TET1 is fused to MLL in a case of pediatric AML containing the t(10;11)(q22;q23). TET1 is a member of a novel protein family, the biologic function of which is unknown. Given that TET1 was independently identified as an MLL fusion partner in another leukemia harboring the t(10;11)(q22;q23), 5 these data confirm that TET1 likely represents the sole recurrent chromosomal target in AML containing this translocation. 
TO THE EDITOR
We have recently completed a study that suggests affinity state measurements may be a useful tool in studies of acute leukemia pathogenesis. Cellular adhesion molecules such as VLA-4 (very late antigen-4; CD49d/CD29) play an important role in the survival of normal and leukemic B cells.
1,2 mAb to VLA-4 inhibits lymphopoiesis, 1 and the binding of VLA-4 on precursor B-ALL cells to its ligand vascular cell adhesion molecule-1 (VCAM-1) on BM stromal cells is required for leukemic cell survival. 2, 3 Defective VLA-4-dependent adhesion has also been identified in a subset of precursor B-ALL cases. 3 Yet, the clinical and biologic significance, if any, to defective VLA-4-mediated adhesion on precursor B-ALL cells is unknown.
VLA-4-mediated adhesion is regulated through affinity changes of VLA-4 for VCAM-1. VLA-4 has several affinity states that are due to conformational changes. We have recently developed a means of detecting these affinity changes, which correspond to the affinity for its natural ligands VCAM-1 and fibronectin, using an FITC-labeled VLA-4-specific peptidomimetic. 4 This technology rests on the observation that when these small molecules are used at a concentration that approximates its affinity constant for the high-affinity state, it will bind to the high-affinity state but not the lower affinity state. The rapid on and off rates of peptidomimetics in contrast to mAbs allow them to be used to detect changes in affinity state in real time. 4 MnCl 2 and TS2/16 are two agents that activate VLA-4 to higher affinity states. TS2/16 binds to VLA-4, inducing a higher affinity state, not dependent on cellular signaling.
In this study, we took advantage of this novel technology to examine how alterations in affinity regulation may affect the clinical or biologic features of precursor B-ALL cases. We first assessed VLA-4 affinity changes on a group of 36 diagnostic samples from patients with precursor B-ALL. These samples were obtained from children diagnosed with precursor B-ALL, and selected from precursor B Phase III trials (COG 9400). The cases consisted of 18 males, four of eight standard risk who achieved CCR and five of ten poor risk who achieved CCR; and 18 females, four of seven standard risk and six of 11 poor risk who achieved CCR. The assays were conducted in a blinded fashion, and the results forwarded to the central data center for statistical analysis. The methods used to quantify monoclonal antibody binding and receptor number peptidomimetic binding have been previously described. 4 After all the results were obtained, we received clinical, laboratory, and immunophenotypic data for each patient from the POG tumor bank. We correlated these data using Kruskal-Wallis and Spearman correlation coefficients to determine r and P values, respectively.
Significant differences in VLA-4 expression between CCR and relapse cases were not observed ( Table 1 ). All patient samples expressed VLA-4; however, a striking range of VLA-4 sites/cell was observed (3015-25 526 sites/cell) with a mean of 7402 sites/cell. In contrast, we have previously shown that normal peripheral blood B cells have approximately 4000 sites/cell with a narrow variation among donors. 4 Site number did not change with Mn or TS2/16 treatment (data not shown). In each patient sample, we next examined the VLA-4 affinity state obtained at rest and after stimulation with MnCl 2 and TS2/16. Fluorescence intensity (MESF) is a measure of the affinity state of VLA-4. A statistically significant association between VLA-4 expression and VLA-4 affinity state measurements was not observed among cases (P ¼ 0.09). There were no significant differences among the CCR and relapse groups in
